Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
NCT06817577

NG004 in Spinal Cord Injury Patients

Led by NovaGo Therapeutics AG · Updated on 2025-02-10

21

Participants Needed

6

Research Sites

88 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004.

CONDITIONS

Official Title

NG004 in Spinal Cord Injury Patients

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Acute incomplete cervical spinal cord injury (lesion between C1 and C8) with confirmed ASIA impairment scale C-D at screening
  • Injury occurred 4 to 28 days before enrollment
  • Not fully dependent on mechanical ventilation
  • Clinically and hemodynamically stable according to acute SCI condition at baseline
Not Eligible

You will not qualify if you...

  • Trauma caused by penetrating injuries like gunshot or knife wounds
  • Multiple clinically relevant spinal cord lesions
  • Major brachial or lumbar plexus damage or trauma
  • Significant head trauma or injury interfering with spinal cord function assessment
  • Severe pre-existing or current systemic diseases such as lung, liver (except uncomplicated Hepatitis A), gastrointestinal, cardiac, immunodeficiency including HIV, kidney disease, or active cancer
  • History or recent episode of Multiple Sclerosis or Guillain-Barre syndrome
  • History of meningitis or meningoencephalitis within past 6 months
  • History of refractory epilepsy
  • History or current autoimmune disease
  • Uncontrolled bleeding disorders or need for anticoagulation not related to SCI
  • Any unstable medical or psychiatric condition
  • Drug dependence within 6 months before trial entry
  • Pregnant or nursing women
  • History of life-threatening allergic or immune reactions
  • Infection around planned spinal needle insertion sites
  • Participation in another clinical study within 4 weeks or longer if required
  • Unconscious patients

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Klinik für Querschnittgelähmte, Klinikum Bayreuth

Bayreuth, Germany

Actively Recruiting

2

Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost

Halle, Germany

Not Yet Recruiting

3

Klinik für Paraplegiologie, Universitätsklinikum Heidelberg

Heidelberg, Germany

Actively Recruiting

4

Zentrum für Rückenmarksverletzte, Unfallklinik Murnau

Murnau am Staffelsee, Germany

Actively Recruiting

5

Swiss Paraplegic Centre

Nottwil, Switzerland

Actively Recruiting

6

Universitätsklinik Balgrist

Zurich, Switzerland

Actively Recruiting

Loading map...

Research Team

D

Director of Clinical Research

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here